Nasdaq · Healthcare
Niagen Bioscience, Inc. (NAGE)
As-reported financials and recent SEC filings for Niagen Bioscience, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$129.4M
Net income
$17.4M
Net margin
13.4%
Diluted EPS
$0.20
ROE
22.7%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $129.4M | $99.6M | $83.6M | $72.0M | $67.4M |
| Gross profit | $83.2M | $61.6M | $50.8M | $42.8M | $41.5M |
| Operating income | $16.3M | $7.7M | $-5.6M | $-18.6M | $-27.1M |
| Net income | $17.4M | $8.6M | $-4.9M | $-16.5M | $-27.1M |
| Diluted EPS | $0.20 | $0.11 | $-0.07 | $-0.24 | $-0.40 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-29
View on EDGAR →S-32026-06-29
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →Largest Healthcare peers
Go deeper on NAGE
Search Niagen Bioscience, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.